History Could Be Repeating, For this Biotech Stock

LAS VEGAS, NV / ACCESSWIRE / March 10, 2016 / Last year around this same time of year Propanc Health Group (PPCH) began an unprecedented 13,000% run which needless to say was huge for investors in the biotech. After an amazing year of progress it looks like PPCH is starting another bullish run ahead of potentially huge news on human trials.

Last year the biotech industry in general took a hit starting in July and PPCH fell with the industry. Now that the industry is rebounding it looks like PPCH is moving ahead in lockstep.

PPCH shares have a 30 day average trading volume of about 5 million shares, but last week the average trading volume was over 11 million shares per day. The turnaround in the share price began slowly with support last week, then Monday saw a huge spike as the stock closed up almost 50% on 23 million shares. Tuesday, and Wednesday were green days as well for PPCH.

It is most likely not a coincidence that exactly 52 weeks ago this company began making one of the largest moves in the market for any security in 2015. If PPCH is poised to repeat a run which saw it hit over 13 cents a share investors should act quickly to maximize profit potential.

As noted PPCH is one of many biotechs making move as the biotechnology industry as a whole recovers. Other biotechs worth a look include; Second Sight Medical Products, Inc. (EYES), Syndax Pharmaceuticals, Inc. (SNDX),Proteostasis Therapeutics, Inc. (PTI), and StemCells, Inc. (STEM), Stemline Therapeutics, Inc. (STML).

However, if investors are looking to maximize upside, PPCH, looks poised for a major breakout and now may be the time to researching PPCH immediately.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $41,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 437690